Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional CO2 Laser + Topical Pentostam for Cutaneous Leishmaniasis
NCT03009422Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Nov 2014
- Primary completion
- Feb 2017
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Light/Condition-Responsive Prodrugs
01
Overview
Randomised, single-blind trial of sodium stibogluconate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Final scar appearance at 6 months. Status: unknown.
02
Drugs
sodium stibogluconate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT03009422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009422.